GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Investigating the Role of DNA Repair Mutations in Prostate Cancer Initiation, Progression, and Susceptibility to Targeted Therapies

$70,910
Sander Barkley Frank · Fred Hutchinson Cancer Research Center · F32 · FY2020 · CA

Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies

$70,904
Timothy An-Thy Chan · Cleveland Clinic Lerner Com-Cwru · U54 · FY2023 · CA

Cancer Therapeutics

$70,697
Eric R Prossnitz · University Of New Mexico Health Scis Ctr · P30 · FY2023 · CA

Cancer Therapeutics

$70,695
Eric R Prossnitz · University Of New Mexico Health Scis Ctr · P30 · FY2024 · CA

Cancer Therapeutics

$70,695
Eric R Prossnitz · University Of New Mexico Health Scis Ctr · P30 · FY2025 · CA

In vivo imaging of mitochondria structure and function in therapy resistant lung tumors

$70,627
David B Shackelford · University Of California Los Angeles · R01 · FY2024 · CA

Cancer Therapeutics

$70,510
Eric R Prossnitz · University Of New Mexico Health Scis Ctr · P30 · FY2022 · CA

Imaging tumor and T cell responses to metabolic and immune modulation therapy

$70,499
Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2018 · CA

Role of the Gut Microbiota in Regulating Responses to anti-PD-1 Cancer Immunotherapy

$70,458
Joon Seok Park · Harvard Medical School · F32 · FY2021 · CA

Translation of a novel combination therapy approach for non-Hodgkin lymphoma

$70,432
Shruthi Naik · Mayo Clinic Rochester · U01 · FY2024 · CA

Control of Microtubule and Genome Integrity by the OBSL1-CUL7-CUL9-p53 Pathway

$70,268
Yue Xiong · Univ Of North Carolina Chapel Hill · R01 · FY2017 · CA

Identifying the role of Ntrk1 in immunosuppression in Kras/p53 mutant lung cancer

$70,146
Jessica Konen · University Of Tx Md Anderson Can Ctr · F32 · FY2020 · CA

Clinical Investigations and Precision Therapeutics

$70,137
Shridar Ganesan · Rutgers Biomedical And Health Sciences · P30 · FY2023 · CA

Tumor-derived Exosome Induction of Dendritic Cell Tolerization

$70,082
Michael Paul Plebanek · Duke University · F32 · FY2022 · CA

Administrative-Core-001

$70,033
Jamey P Weichert · University Of Wisconsin-Madison · P01 · FY2022 · CA

Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response

$70,033
Jamey P Weichert · University Of Wisconsin-Madison · P01 · FY2022 · CA

Immuno/Oncology (IO)

$70,009
Scott J Antonia · Duke University · P30 · FY2025 · CA

The Impact of ATR Kinase Inhibitors on CD8+ T Cell Expansion and Memory Development

$69,960
Christopher J. Bakkenist · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA

Epigenetic therapy for pancreatic cancer

$69,950
Gaoyang Liang · Salk Institute For Biological Studies · F32 · FY2019 · CA

Cancer Biology Program

$69,947
Ann Marie Pendergast · Duke University · P30 · FY2021 · CA

Epigenetic regulators of subtype plasticity in bladder cancer

$69,802
John Robert Christin · Columbia University Health Sciences · F32 · FY2022 · CA

Development of Novel Therapies for HIV Infection

$69,771
Robert Yarchoan · Division Of Clinical Sciences - Nci · ZIA · FY2018 · CA

The Role of NK Cells in Mediating the Immune Response in Irradiated HNSCC

$69,690
Thomas E Bickett · University Of Colorado Denver · F32 · FY2021 · DE

Immune Checkpoint Regulation by the Integrated Stress Response Pathway in Lung Ca

$69,500
Shayna Thomas-Jardin · Ut Southwestern Medical Center · F32 · FY2023 · CA

Studies of Materials with Physiological Properties

$69,426
Harvard University · R01 · FY2005 · GM